WO1999024400A1 - Esters de probucol et leurs utilisations - Google Patents

Esters de probucol et leurs utilisations Download PDF

Info

Publication number
WO1999024400A1
WO1999024400A1 PCT/US1998/023746 US9823746W WO9924400A1 WO 1999024400 A1 WO1999024400 A1 WO 1999024400A1 US 9823746 W US9823746 W US 9823746W WO 9924400 A1 WO9924400 A1 WO 9924400A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
probucol
compound
administering
treatment
Prior art date
Application number
PCT/US1998/023746
Other languages
English (en)
Inventor
Sheldon S. Hendler
Robert A. Sanchez
Jan Zielinski
Original Assignee
Vyrex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyrex Corporation filed Critical Vyrex Corporation
Priority to AU13873/99A priority Critical patent/AU1387399A/en
Publication of WO1999024400A1 publication Critical patent/WO1999024400A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Definitions

  • Tins invention relates to the field of pharmaceuticals. More specifically, this invention relates to novel water-soluble esters of probucol for administration as antioxidants and pro-drugs of probucol. More specifically, the present invention relates to pharmaceutical formulations comprising novel water-soluble phosphate esters of probucol.
  • Probucol is a water-insoluble antioxidant.
  • Probucol is structurally related to the widely used food additives 2,[3]-tert-butyl-4-hydroxyanisole (BHA) and 2,6-di-tert-butyl-4- methylphenol (BHT).
  • BHA 2,[3]-tert-butyl-4-hydroxyanisole
  • BHT 2,6-di-tert-butyl-4- methylphenol
  • Probucol has also been used as a pharmaceutical agent to treat a variety of infections, traumas, and pathologic conditions, including, e.g., to lower serum cholesterol levels in hypercholesterolemic patients (Zimetbaum (1990) J. Clin. Pharmacol. 30:3-9; Schwartz (1988) Am. J. Cardiol.
  • Probucol is commonly administered in the form of tablets typically containing celluloses and other excipients.
  • Administration of the tablet form of probucol can present difficulties because probucol is absorbed at significantly different rates and in different amounts by different patients (see, e.g., Heeg (1980) Laendere Medicale 9(40):2990-4).
  • Some success in finding an alternative to tablet delivery of probucol has been achieved by use of a solution of probucol in a triglyceride oil. This formulation can enhance systemic absorption of the drug (Sanchez, et al, U.S. Patent 5,494,936).
  • probucol is both highly crystalline and highly lipophilic, which makes it almost totally insoluble in water, it is poorly absorbed into the blood, and much of it is excreted in a substantially unchanged form. Thus, this extremely low solubility of probucol hinders its therapeutic efficacy and limits the therapeutic applications of the drug. Unsuccessful attempts have been made to solve these problems by converting probucol to water-soluble pro-drug derivatives; see, e.g., Parthasarathy, et al, U.S. Patent 5,262,439. Because probucol has these various problems, an alternative means of delivery, or formulations of probucol, having improved absorption characteristics or stability properties, would be highly desirable.
  • the present invention fulfills these and other needs.
  • the invention provides a probucol ester of the formula:
  • Xi is H- or - PO 3 -H 2
  • X 2 is H- or - PO 3 -H
  • R* and R 2 are H- or -CH 3
  • R 3 , Rat, R 5 , and R are independently selected from H- or an alkyl group selected from the group consisting of methyl, ethyl, propyl, butyl or tert-butyl; or, a pharmaceutically acceptable salt thereof.
  • R 3 , R 4 , R 5 , and R ⁇ are tert-butyl groups.
  • the invention also provides a diprobucol ester of the formula
  • Xi is H- or - PO 3 -H 2
  • X 2 is H- or - PO 3 -H 2
  • Ri and R 2 are H- or -CH 3
  • R 3 , R , R 5 , and R$ are independently selected from H- or an alkyl group selected from the group consisting of methyl, ethyl, propyl, butyl or tert-butyl; or, a pharmaceutically acceptable salt thereof.
  • R 3 , R 4 , R 5 , and R 6 are tert-butyl groups.
  • the invention provides for a lithium probucol compound of the formula:
  • X* is a lithium
  • X 2 is H- or a lithium
  • R ! and R 2 are H- or -CH 3
  • R 3 , R 4 , R 5 , and ⁇ are independently selected from H- or an alkyl group selected from the group consisting of methyl, ethyl, propyl, butyl or tert-butyl; or, a pharmaceutically acceptable salt thereof.
  • R 3 , R , R 5 , and R ⁇ are tert-butyl groups.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of a probucol ester or diprobucol ester of the invention.
  • the pha ⁇ naceutical composition can be in a unit dosage form; the unit dosage foim can contain between about 0J mg per kg to about 1 gm per kg, between about 1.0 mg per kg to about 100 mg per kg, or between about 10 mg per kg to about 50 mg per kg .
  • the pharmaceutical composition can be in an aqueous solution, a solid, a liposome, a transdermal carrier, a detergent or an emulsifier. It can be formulated as a powder, a tablet, a capsule or a lozenge.
  • the pharmaceutical composition can be administered by intramuscular, intravenous, intraperitoneal (I.P.), intrathecal, intradermal, oral, rectal, nasal, ocular, transdermal, or topical routes, or as an inhalant.
  • the pharmaceutical composition is in the form of an injectable solution, and the concentration of the compound in the injectable solution can be between about 1 mg/ml to about 100 mg/ml.
  • the pharmaceutical composition can be contained in an aerosolizer or inhaler, or can be contained in a transdermal delivery system.
  • the invention also provides for a method for inhibiting oxidation or oxidative damage in a biological material or an organism comprising administering to the material or organism an effective amount of a probucol ester of the invention.
  • the biological material can be a biological solution, a cell, or a tissue.
  • the organism can be a plant, an animal, or a human.
  • the effective amount can be between about 0J mg per kg to about 1 gm per kg, between about 1.0 mg per kg to about 100 mg per kg, between about 10 mg per kg to about 50 mg per kg; or between about 1.0 mg per kg to about 1 gm per kg .
  • the pharmaceutical composition can be administered intramuscularly, intravenously, intraperitoneally, intrathecally, intradermally, orally, rectally, nasally, ocularly, transdermally, topically or as an inhalant.
  • the methods include prophylactic or therapeutic treatment of a condition with an inflammatory component in a subject, comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the probucol ester can be administered in the form of an intravenous injection of a pharmaceutical formulation and a pharmaceutically acceptable aqueous carrier.
  • the concentration of the probucol ester in the aqueous composition is between about 1 mg/ml to about 100 mg/ml; and is between about 1 mg/ml to about 20 mg/ml.
  • Oxidation or oxidative damage can be mediated by one or more enzymes, e.g., myeloperoxidase, superoxide dismutase, nitric oxide synthase and the oxidative repiratory burst enzymes neutrophils and macrophages.
  • Oxidation or oxidative damage in a biological material or an organism can also be mediated by drugs, infectious agents, toxins, pollutants, heavy metals or radiation.
  • the invention provides a method for the prophylactic or therapeutic treatment of a viral infection in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the viral infection can be, but is not limited to, a herpes virus infection, a cytomegalovirus infection, a retroviral infection, or a human immunodeficiency virus infection.
  • the retroviral infection can be an HIV-1 infection.
  • the viral infection can be sexually or non-sexually transmitted.
  • the compound is applied topically or is administered ex vivo, as in the ex vivo treatment of cells, such as, e.g., lymphocytes.
  • the method is for the treatment of a viral infection in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention, wherein said administering to the subject comprises the ex vivo treatment of cells, such as, e.g., lymphocytes.
  • the invention provides a product of manufacture for the prophylactic treatment of a viral infection in a subject comprising a pharmacologically effective amount of a probucol ester of the invention.
  • the product of manufacture can be a lubricant for sexual intercourse, a condom, or other prophylactic device.
  • the invention provides a method for the prophylactic or therapeutic treatment of reperfusion injury in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the reperfusion injury can be caused by - a consequence of - a cerebrovascular accident ("stroke"), myocardial infarction or trauma.
  • stroke cerebrovascular accident
  • the invention provides a method for the prophylactic or therapeutic treatment of restenosis in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the restenosis can occur after angioplasty (e.g., percutaneous transluminal coronary angioplasty or PTCA), coronary bypass surgery, cardiovascular surgery or a lytic procedure (e.g., streptokinase treatment).
  • the invention provides a method for the prophylactic or therapeutic treatment of hypercholesterolemia in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the invention provides a method for the inhibition of the oxidation of low density lipoproteins in a subject, comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the invention provides a method for the prophylactic or therapeutic treatment of a peripheral neuropathy in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the invention provides a method for the prophylactic or therapeutic treatment of a pathologic condition of the central nervous system (CNS) in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the pathological CNS condition can be caused by the neurotoxicity effected by oxidative stress or beta-amyloid neurotoxicity.
  • the condition can be, e.g., Alzheimer's Disease, traumatic brain injury, traumatic spinal chord injury, Parkinson's disease, Huntington's disease, Pick's disease, and dementias in general.
  • the invention provides a method for the prophylactic or therapeutic treatment of an opthalmic disorder in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the opthalmic disorder can be macular degeneration.
  • the invention provides a method for the prophylactic or therapeutic treatment of a hearing disorder in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the hearing disorder can be noise-induced hearing loss.
  • the invention provides a method for the prophylactic or therapeutic treatment of a pulmonary disorder in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the pulmonary disorder can be asthma, acute respiratory distress syndrome (ARDS), or chronic obstructive pulmonary disease (COPD).
  • the invention provides a method for the prophylactic or therapeutic treatment of a cardiovascular disease in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the cardiovascular disease can be reperfusion injury, atherosclerosis, cerebrovascular accident ("stroke”), restenosis, myocardial infarction ("heart attack”), or elevated cholesterol or LDL oxidation.
  • the invention provides a method for inhibiting cholesterol oxide formation in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the invention provides a method for the inhibition of macrophage foam cell formation in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the invention provides a method for the inhibition of oxysterol synthesis in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the oxysterol can be 7 beta-hydroxycholesterol or 7-ketocholesterol.
  • the invention provides a method for the inhibition of oxidative damage (i.e., peroxidation) associated with diabetes mellitus in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention
  • the invention provides a method for the prophylactic or therapeutic treatment of a drug-induced oxidative stress in a subject comprising administering to the subject a pharmacologically effective amount of a probucol ester of the invention.
  • the drug can be a chemotherapeutic agent or an antitumor drug, and, without limitation, the chemotherapeutic agent can be bleomycin or adriamycin.
  • the invention provides a method for the treatment of a cancer in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the cancer both alone and in combination with chemotherapeutic agents, and also in combination with radiotherapeutic agents.
  • the invention provides a method for the treatment of an arthritis in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the arthritis.
  • the arthritis can be rheumatoid arthritis, psoriatic arthritis, or osteoarthritis.
  • the invention provides for a method for the treatment of pre-eclampsia and eclampsia in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the pre-eclampsia or eclampsia.
  • the invention provides for a method for the treatment of infertility due to, amongst other things, increased oxidative stress in a male or female subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the infertility.
  • the invention provides for a method for the treatment of endometriosis.
  • the invention provides for a method for the treatment of erectile dysfunction.
  • the invention provides a composition comprising a bio-organic material and an amount of a probucol ester of the invention effective to inhibit oxidation of the bio- organic material.
  • the bio-organic material can be, e.g., a blood plasma preparation, a nutrient media, a protein, a pharmaceutical, a cosmetic, a sperm or a oocyte preparation, cells or a cell culture, a virus, a food, a drink, an implant material or an implantable device, a medical materials or a container for bio-organic material.
  • biological material refers to bioorganic molecules, cells, tissues, organs, organisms, extracts, homogenates, fluids or cultures, both in vitro and in vivo.
  • condition refers to any physiologic state that is not optimally normal or healthy, including, e.g., an injury, infection, disease, pathology, drug side effect, contamination (as e.g., a pollutant), poisoning, i ⁇ itation, predisposition (e.g., as in a genetic predisposition) or abnormal blood chemistry (e.g., elevated cholesterol or elevated LDL).
  • inflammatory component as used herein incorporates its common usage and refers to that component of an injury, disease or condition involving the immune response, particularly, the damaging oxidating compositions generated directly or indirectly by an immune reaction/response.
  • many, if not most, diseases, conditions and injuries involve an inflammatory component which contributes directly or indirectly to pathogenesis and tissue damage.
  • the probucol esters of the invention as antioxidants, can ameliorate and prevent these deleterious inflammatory insult(s).
  • oxidative stress refers to an imbalance between production of reactive oxygen species and antioxidant protection resulting in overproduction of at least one reactive oxygen species, including, e.g., superoxide anion, hydroxyl radical, hydrogen peroxide, peroxynitrite, hypochlorite, or alkylperoxide.
  • a reactive oxygen species including, e.g., superoxide anion, hydroxyl radical, hydrogen peroxide, peroxynitrite, hypochlorite, or alkylperoxide.
  • MDA malondialdehyde
  • isoprostanes oxidized glutathione; glutathione peroxidase; superoxide dismutase (SOD) or catalase.
  • oxidative stress include detection of serum levels of TB.ARS (thiobarbituric acid reaction substances), isoprostanes, 8-hydroxy-2-deoxyguanosine, protein bound acrolein, methionine sulfoxide, oxidized glutathione and nitrotyrosine (see, e.g., Pereira (1998) Braz. J. Med. Biol. Res. 31:827-833; Tsai (1998) Gut 42:850-855; De La Cruz (1998) Brain Res. 800:136-144; Paolisso (1998) J. Am. Geriatr. Soc.
  • composition refers to a composition suitable for pha ⁇ naceutical use in a subject.
  • the pharmaceutical compositions of this invention are formulations that comprise a pharmacologically effective amount of a probucol ester and a pharmaceutically acceptable carrier.
  • a “pharmacologically effective amount (or dose)” is the amount of compound (e.g., a pharmaceutical composition comprising a probucol ester of the invention) administered to the individual to prophylactically or therapeutically effectively treat an individual for an injury, disease, infection, drag side effect, or other condition; e.g., inhibition or prevention of oxidation (such as, e.g., lipid oxidation), treatment of peripheral neuropathies, central nervous system diseases, neurovascular disorders associated with diabetes, opthalmic disorders, hearing disorders, pulmonary disorders, viral infections, cardiovascular diseases, hypercholesteremia, pre-eclampsia and eclampsia, male and female infertility, endometriosis, and the like.
  • oxidation such as, e.g., lipid oxidation
  • pharmaceutically acceptable salt is a salt that can be formulated into a compound for pharmaceutical use including, e.g., metal salts (e.g., sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
  • metal salts e.g., sodium, potassium, magnesium, calcium, etc.
  • salts of ammonia or organic amines e.g., probucol ester compounds in the form of pharmaceutically acceptable salts.
  • probucol refers to a composition also known by the chemical designations " [4,4'-(isopropylidenedithio)bis(2,6-di-tert-butylphenol)]" and "bis(3,5-di-tert- butyl-4-hydroxyphenyl) acetone mercaptole.” Probucol has been commercially available as a drag under the trademark Lorelco® (Marion Merrell Dow Pharmaceuticals, Inc., Kansas City, MO).
  • probucol has been commercially available as a drag under the trademark Lorelco® (Marion Merrell Dow Pharmaceuticals, Inc., Kansas City, MO).
  • probucol has been commercially available as a drag under the trademark Lorelco® (Marion Merrell Dow Pharmaceuticals, Inc., Kansas City, MO).
  • probucol has been commercially available as a drag under the trademark Lorelco® (Marion Merrell Dow Pharmaceuticals, Inc., Kansas City, MO).
  • probucol has been commercially available as a
  • a prophylactic device can be a male or female condom or other barrier device, a spermicide, a contraceptive foam, and the like.
  • subject refers to treatment of an animal, such as a mammal, including a human.
  • Non-human animals subject to treatment include, for example, fish, birds, and mammals such as cows, sheep, pigs, horses, dogs and cats.
  • tablette is used in its common context, and refers to a solid composition made by compressing and/or molding a mixture of compositions in a form convenient for swallowing or application to a body cavity.
  • applied topically refers to any non-internal application or adminstration of a compound, i.e., any ex vivo application or administration.
  • treatment refers to prophylactic and therapeutic treatment administered to a subject.
  • Prophylactic treatment includes administering treatment to an individual who does not have a disease or condition, or does not exhibit signs of a disease or condition, or exhibits only early signs of a disease or condition for the purpose of decreasing or abrogating the risk of acquiring the disease or condition or decreasing or abrogating a symptom or a pathologic condition arising from or related to the disease or pathology.
  • Such an early sign can be, e.g., elevated seiiim cholesterol.
  • administration of a probucol ester of the invention has a prophylactic or treatment effect in inhibiting, ameliorating or preventing oxidative tissue damage in a person who is exposed to an oxidant, has experienced a trauma, or who is considered a high risk for developing a disease or condition with an inflammatory component, has a prophylactic or treatment effect in inhibiting, ameliorating or preventing oxidative tissue damage.
  • Therapeutic treatment includes administering treatment to an individual who exhibits signs of pathology or injury due to disease, trauma, or other condition, or is considered at risk for developing or incurring such a condition (disease or injury), for the purpose of preventing, diminishing, ameliorating or eliminating any injury, tissue or chemical damage or pathology.
  • the invention provides for novel phosphoric acid derivatives of probucol.
  • the probucol esters of the invention are significantly more water-soluble than probucol, making them extremely useful as improved, probucol-based pharmaceuticals.
  • the probucol esters of the invention are useful as antioxidants and as pro-drags of probucol.
  • Preferred probucol ester embodiments are probucol monophosphate and probucol diphosphate.
  • the water-insolubility of probucol interferes with the predictability of its absorption by the body and makes it very difficult to administer in aqueous vehicles.
  • the polar probucol esters of the invention being significantly more soluble in water, clinically significantly enhance systemic absorption.
  • the probucol esters once absorbed, can be hydrolyzed to additional pharmacologically active forms; e.g., probucol diphosphate is hydrolyzed to probucol monophosphate and probucol, and the monophosphate form is hydrolyzed to probucol.
  • the probucol ester Once the probucol ester has been hydrolyzed to probucol, it re- partitions from an aqueous medium to a biological lipophilic medium, such as a cell membrane lipid bilayer or lipoprotein.
  • the probucol esters of the invention can act as probucol pro-drugs.
  • This invention also provides a variety of probucol-based pharmaceuticals which can be administered in aqueous vehicles, e.g., intravenously, intraperitoneally, intrathecally, orally, as an inhalant or spray, and the like.
  • the only readily chemically reactive functionalities in probucol are its two phenolic hydroxyl groups. Since both phenolic hydroxyl groups are flanked by bulky tertiary-butyl substituents, they are blocked and therefore highly unaccessible. Adding a functional group to the phenolic oxygens is thus very difficult.
  • a phosphate ester of probucol with improved solubility and stability properties has presented many difficulties.
  • dozens of attempts to react probucol with highly active phosphorylation reagents, such as phosphorous oxychloride and phosphoric anhydride, under a variety of conditions, e.g., tertiary amine catalysis, activating solvents, high temperature failed to produce any detectable yield of probucol phosphate esters.
  • the invention includes the discovery that phosphorylation of probucol can be achieved if the phenolic hydroxyls are fully ionized prior to reaction with phosphorous oxychloride.
  • Probucol phosphate esters prove to be quite stable to hydrolysis under both strongly acidic conditions, as low as a pH of about 1, and strongly alkaline conditions, as high as a pH of about 14.
  • probucol diphosphate has an estimated half-life of three weeks at pH 1, hydrolyzing to probucol monophosphate. Under these conditions, no significant hydrolysis to the unphosphorylated probucol occurs.
  • probucol diphosphate does not measurably hydrolyze (see Example 6, below).
  • Probucol diphosphate has an estimated half-life of 15 hours at a pH of between 4 and 6, hydrolyzing to probucol monophosphate; and an estimated half-life of 2 weeks at a pH of between 4 and 6 for complete ester hydrolysis to probucol.
  • the estimated half-life of probucol diphosphate hydrolyzing to its monophosphate and unphosphorylated forms is 30 hours and 4 weeks, respectively (see Example 6).
  • probucol diphosphate ester is converted cleanly and sequentially to probucol monophosphate ester, and thence probucol.
  • this hydrolytic conversion of probucol phosphate esters to probucol occurs at a pharmacologically significant rate in vivo (which is related to the concentration of probucol that is needed to achieve a therapeutic effect).
  • the probucol ester pharmaceutical compositions of the invention in addition to acting as anti- oxidants in the phosphorylated foirm (in an aqueous medium), also function as efficacious pro-drags of probucol (which partitions into a lipophilic medium).
  • the utility of the probucol esters of the invention are not limited by any particular mechanism of action, such as their ability to hydrolyze to probucol in vivo.
  • Probucol diphosphate ester is fully soluble in aqueous buffers and does not form micelles. Taking advantage of these different rates of phosphate ester group hydrolysis and different relative water solubilities, in different embodiments, formulations of the invention can include only one particular probucol ester specie, such as only diphosphate probucol, only monophosphate probucol, only diprobucol phosphate, or varying amounts of any probucol ester of the invention. In other embodiments of the invention, probucol is included in a foimulation with one of the novel probucol esters of the invention.
  • the monophosphate and diphosphate esters of probucol are demonstrated by the Examples set forth herein as effective antioxidant pharmaceuticals.
  • the probucol ester compounds of this invention are useful as pharmaceutical agents to prevent or inhibit the oxidation of biological molecules and materials.
  • the invention provides a method for inhibiting oxidation in a biological material, e.g., a cell, a tissue, or an organism, comprising administering a probucol ester of the invention in an amount effective to inhibit the oxidation.
  • a biological material e.g., a cell, a tissue, or an organism
  • Such inhibition can be extremely beneficial, because oxidation can be a source of serious damage to or premature loss (as through clearance or inactivation) of bioorganic molecules, including nucleic acids, proteins, lipids and carbohydrates.
  • the source of oxidants can be external to an organism, e.g., from the environment, or internal, e.g., as a result of the natural or pathogenic production of free radicals or other oxidizing agents.
  • Reactive oxygen species including free radicals
  • a system including antioxidant enzymes and scavenger molecules serves to inhibit oxidation of biological molecules by these oxidants (e.g., reactive oxygen species and free radicals), thus protecting membrane lipids, proteins, carbohydrates, and nucleic acids (e.g., DNA and RNA).
  • Oxidative stress in tissues can be provoked by an augmented metabolic rate, a decrease in the antioxidant capacity, or many other factors.
  • a natural source of oxidative stress arises from the fact that molecular oxygen has two unpaired electrons in its outer valence shells. The univalent reduction of molecular oxygen generates a reactive radical called superoxide. The reductive environment of the cellular milieu provides ample opportunities for oxygen to undergo univalent reduction.
  • Oxidative damage to biological material can also be caused by various enzymatic reactions related to the mitochondria (the stepwise reduction of oxygen by the mitochondrial electron-transport chain to produce water), the inflammatory process (discussed below), and the like.
  • the oxidative damage can be in part mediated by an enzyme such as, e.g., myeloperoxidase, superoxide dismutase or nitric oxide synthase.
  • the probucol esters of the invention can be used to prevent or ameliorate such oxidative damage.
  • Cigarette smoke can create oxidative stress, primarily through chemical modification of glutathione as a major damage mechanism (Maranzana (1998) Arch. Biochem. Biophys. 350:169-182). Oxidative stress as a causative agent in cancer is discussed below.
  • the probucol esters of the invention can be used to prevent or ameliorate such environmental damage.
  • the probucol esters of the invention as effective anti-oxidants in vivo, can treat or prevent oxidative stress and the damage directly or indirected induced by this stress (e.g., caused by inflammatory components of an immune response) of a wide variety of injuries, degenerative processes, diseases and syndromes, and other conditions.
  • mutagenesis agenesis of cell transformation and cancer
  • atherosclerosis arteriosclerosis
  • myocardial infarction myocardial infarction
  • strokes cerebrovascular accidents
  • ischemia/reperfusion injury and restenosis ischemia/reperfusion injury and restenosis
  • pre-eclampsia and eclampsia neurovascular disease associated with diabetes
  • chronic renal failure patients undergoing peritoneal dialysis or hemodialysis chronic inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, osteoarthritis, lupus erythematosus and psoriatic arthritis
  • acute inflammatory problems such as wound healing, photo-oxidative stresses to the eye (such as cataract) and to the skin (as in melanoma and other skin cancers), hearing loss (such as noise-induced hearing loss), central-nervous-system disorders, such as certain forms of familial amyotrophic lateral sclerosis, certain glutathione peroxidase-
  • Oxidative stress is also implicated in the pathological processes resulting from CNS trauma, including spinal cord injury. Some of these oxidation-linked diseases or disorders can be exacerbated, perhaps even initiated, by numerous environmental pro-oxidants and/or pro-oxidant drags and foods. Oxidative stress is also associated with infections, e.g., infections by mammalian viruses, particularly those with lipid membranes.
  • the probucol ester compounds of this invention are useful as anti-oxidative pharmaceutical agents to prevent or inhibit the oxidative stress and damage caused by or associated with all of these conditions .
  • the probucol esters of the invention are useful in the treatment, amelioration and prevention of conditions having an inflammatory component.
  • the invention provides a method for the treatment of a condition with an inflammatory component in a subject, comprising administering to the subject a probucol ester of the invention in an amount effective to treat the condition.
  • Many, if not most, diseases and injuries involve an inflammatory component which contributes to the pathogenesis or damage caused by the condition.
  • the probucol esters of the invention, as anti-oxidants are useful as pharmaceuticals in the treatment and prevention of deleterious inflammatory insult(s). While the invention is not limited to or by a particular theory of operation, the compositions of the invention decrease the amount of damaging oxidating compositions generated by the inflammatory response.
  • Inflammation is characterized at the cellular level by the production of inflammatory mediators, such as cytokines and eicosanoids, e.g., prostaglandins, prostacyclins, thromboxanes and leukotrienes.
  • cytokines and eicosanoids e.g., prostaglandins, prostacyclins, thromboxanes and leukotrienes.
  • inflammation is characterized by invasion of leukocytes, especially neutrophils, macrophages and lymphocytes.
  • neutrophils when stimulated, generate reactive oxygen species, including myeloperoxidase-derived hypochlorous acid, or HOC1.
  • Neutrophils can oxidize nearly all of the amino acids commonly found in plasma to a corresponding family of aldehydes in high yield.
  • the reaction is mediated by hypochlorous acid (HOC1), the major oxidant generated by the myeloperoxidase-H2O2-Cl- system of phagocytes.
  • HOC1 hypochlorous acid
  • the production of prostaglandins, prostacyclins and thromboxanes typically involve an oxidation step that is cyclooxygenase dependent.
  • protein nitration is a final product of the production of highly reactive nitrogen oxide intermediates (e.g., peroxynitrite) formed in reactions between nitric oxide (NO) and oxygen-derived species such as superoxide.
  • the enzyme prostaglandin H synthase-2 forms one or more tyrosyl radicals during its enzymatic catalysis of prostaglandin formation.
  • Arachidonic acid an unsaturated fatty acid constituent of the phosphohpid domain of cell membranes, is released via mobilization of phospholipases, is subject to free radical attack and peroxidation, generating F2-isoprostanes.
  • Disease and conditions with inflammatory components which can be treated or prevented using the probucol ester compositions of the invention include, but are not limited to, e.g., those listed above as associated with oxidative stress.
  • the anti-oxidant probucol esters of the invention are effective anti-viral and anti-retroviral agents.
  • the invention provides a method for the treatment of a viral infection in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the viral infection. While the invention is not limited to or by a particular theory of operation, the anti-viral and anti-retroviral efficacy may be through an effect on viral membrane fluidity, or the anti-oxidant' s ability to prevent lipid peroxidation, or their preferential solubility in viral lipid membranes, or a combination of these or other mechanisms.
  • anti-oxidant probucol esters are effective as antiviral agents against mammalian viruses, particularly those with lipid membranes, such as, e.g., herpes viruses, such as herpes simplex viruses, e.g., herpes simplex virus 1 (HSV1) or herpes simplex virus (HSV2), and human herpes virus 6 (HHV6), HHV7, and HHV8); cytomegalovirus (CMV); Epstein Barr virus (EBN); varicella zoster virus (NZN); paramyxovirus; vaccinia virus (Baek (1997) J. Biol Chem.
  • herpes viruses such as herpes simplex viruses, e.g., herpes simplex virus 1 (HSV1) or herpes simplex virus (HSV2), and human herpes virus 6 (HHV6), HHV7, and HHV8)
  • CMV cytomegalovirus
  • EBN Epstein Barr virus
  • NZN varicella
  • retrovirases such as HIN-1 (Munoz-Barroso (1998) J. Cell. Biol. 140:315-323), HIN-2, HTLV-1, HTLN- 2; Ebola virus (Ruiz-.Arguello (1998) J. Virol. 72:1775-1781); and, Marek's disease virus.
  • the anti- viral and anti-retroviral efficacy of the anti-oxidant probucol esters of the invention can also be through their ability to ameliorate oxidative stress, i.e., to decrease the levels of reactive oxygen species in an individual. Increased levels of reactive oxygen species are implicated in the regulation of mammalian transcription factors, including nuclear factor ⁇ F B and API .
  • ⁇ FKB and API are influenced by cellular redox status, and have been implicated in the transcriptional regulation of a wide variety of genes involved in the cellular inflammatory process and tissue destruction.
  • NFKB is believed to play a central role in the inflammatory cellular process (see, e.g., Winyard (1997)
  • the anti-oxidant probucol esters of the invention in decreasing the severity of or inhibiting oxidative stress and lowering levels of NFKB, are effective anti-retroviral pharmaceutical reagents.
  • the probucol esters can be used alone or in combination with other anti-HIV pharmaceuticals for patients with .AIDS.
  • apoptosis Programmed cell death (apoptosis) of T-lymphocytes observed in HIV infected individuals has been linked to oxidative stress. Reactive oxygen species induce apoptosis, which contributes to the cell loss during progression of HIV- 1 infection. Reactive oxygen species-induced apoptosis is significantly enhanced in HIV-infected subjects even in the very early stages after infection. Moreover, reactive oxygen species-mediated apoptosis is not restricted to a particular lymphocyte subset (Dobmeyer (1997) Free Radic. Biol. Med. 22:775-785).
  • administering are effective in decreasing the amount of reactive oxygen species-mediated apoptosis contributing to the deletion of lymphocytes and to the pathogenesis of .AIDS.
  • the anti-oxidant probucol esters of the invention can also be used in the ex vivo treatment of cells infected with retrovirases.
  • HIV infected CD4+ helper T cells can be removed from the patient, treated with the probucol esters of the invention ex vivo, and reinfused.
  • ex vivo manipulation of lymphocytes has been done, for example, with autologous CD8+ cytotoxic T cells enriched for HIV-specific cytotoxicity targeted against a diversity of HIV epitopes (Lieberman (1997) Blood 90:2196-2206; Wilson (1995) J. Infect. Dis. 172:88-96).
  • Probucol has been shown to have anti-viral activity against adult patients with
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the treatment of viral and retroviral infection and disease.
  • the anti-oxidant probucol esters of the invention are effective pharmaceutical agents in the treatment and prevention of reperfusion injury that is the result of surgery (e.g., cardiac surgery, such as bypass surgery, or organ transplantation), injury, infarctions (e.g., heart attacks or cerebral ischemia/stroke), fibrinolytic procedures (e.g., streptokinase) and the like.
  • the invention provides a method for the treatment of reperfusion injury in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the reperfusion injury.
  • compositions of the invention can be pharmacologically efficacious by decreasing the amount of oxidatively damaged tissue, especially, vascular muscle tissue.
  • Oxygen free radicals play a major role in ischemic injury, particularly when followed by reperfusion. Involvement of oxygen free radicals in ischemia-/reperfusion injury is based on measurements of increased products of lipid peroxidation after organ ischemia and restoration of blood flow during surgical operations and reperfusion of organ transplants.
  • ischemia/reperfusion of human skeletal muscle involves both xanthine oxidase-dependent oxygen free radicals and cyclooxygenase metabolites.
  • nNOS neuronal isoform of nitric oxide synthase
  • NO nitric oxide
  • the immunologic isoform of NOS (iNOS) not normally present in healthy tissue, is induced shortly after ischemia and contributes to secondary late-phase damage.
  • delayed post-ischemic hypoperfusion develops after a preceding phase of post-ischemic hyperemia and is characterized by increased vasotonus.
  • hypoperfusion is associated with dysfunction in metabolism and blood flow caused, in part, by the generation of free radicals and possibly down-regulation of endothelial nitric oxide synthase.
  • Current treatment of post-ischemic hypoperfusion which includes neutrophil elimination and free radical scavengers, is still unsatisfactory.
  • Use of the probucol esters of the invention can be an important adjunct in the treatment of ischemic cell injury, especially in the case of cerebral ischemia, organ transplantation, peripheral artery occlusion, and heart surgery.
  • Probucol esters can also be used adjunctively with reperfusion protocols, as in the treatment of myocardial infarction with balloon angioplasty or in the treatment of stroke with fibrinolytic agents.
  • Prophylactic use of probucol esters before a reperfusion procedure can abrogate or ameliorate the severity of reperfusion injury.
  • the inflammatory response to cardiopulmonary bypass and reperfusion procedures is the product of a complex interplay of humoral and cellular components.
  • Contact activation cascades, the complement system, and cytokines comprise the humoral elements and interact in such a way as to propagate their own cascades and to activate the cellular elements.
  • Cellular components include neutrophils and endothelial cells, which become involved after their activation by humoral mediators.
  • Neutrophil-endothelial cell adherence is the initial step of the cellular inflammatory response. It is promoted by the expression of specific adhesion molecules on the surfaces of both of these cells. This leads to the emigration of neutrophils into the extravascular space where they release toxins, including oxidants, that damage surrounding tissues.
  • the resulting organ dysfunction produces the clinical picture referred to as the "postperfusion syndrome.”
  • Strategies to attenuate this response including the administration of corticosteroids, aprotinin, and anticytokine monoclonal antibodies, are inadequate to prevent or significantly ameliorate resultant tissue damage.
  • the probucol esters of the invention can be used as clinically efficacious agents to better prevent such injury.
  • Probucol has been shown to have a protective effect on myocardium with respect to ischemia-reperfusion arrhythmia in an isolated rat heart (Tada (1992) Can. J. Cardiol 8:975-980).
  • the effects of short-term (7 days) or long-term (24 weeks) administration of 1% probucol on the size of infarcts resulting from 30 minutes of coronary occlusion followed by reperfusion (for 48 hours) in hyperlipidemic rabbits demonstrated that infarction lesions in untreated rabbits were significantly larger than those in the rabbits receiving the long-term treatment with probucol.
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the treatment and prevention of reperfusion injuries.
  • Probucol Esters as Pharmaceutical Agents to Treat Restenosis Restenosis after coronary angioplasty is a major limitation of an otherwise highly effective and safe procedure for the treatment of atherosclerotic coronary artery disease.
  • the invention provides a method for the prevention and treatment of restenosis in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to prevent and treat the restenosis.
  • Neointimal thickening also refeired to as neointimal hyperplasia, occurs in response to arterial injury and coronary (balloon) angioplasty.
  • This hyperplastic process involves different steps which include smooth muscle cell activation, proliferation, and migration, and the production of extracellular matrix.
  • the factors which control neointimal thickening include growth factors, hormonal factors, and mechanical factors.
  • Neointimal formation and arterial wall remodeling are pivotal causes of luminal narrowing in both atherogenesis and restenosis. .
  • Arterial remodeling refers to a series of dynamic structural changes - such as lumen loss and restenosis - that arteries may undergo in response to various stimuli, including changes in blood flow and pressure, and acute injury.
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the treatment and prevention of restenosis. Such treatment would not only reduce morbidity and mortality but would also significantly reduce medical expenses.
  • the anti-oxidant probucol esters of the invention are effective pharmaceutical agents in the treatment and control of hypercholesterolemia and hyperlipidemia.
  • the invention provides a method for the treatment of hypercholesterolemia or lipidemia in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the hypercholesterolemia or lipidemia. While the invention is not limited to or by a particular theory of operation, the compositions of the invention can be pharmacologically efficacious by various mechanisms, including inhibiting the oxidation of low density lipoproteins (LDLs). Probucol was found to significantly reduce serum levels of cholesterol and lipids.
  • LDLs low density lipoproteins
  • probucol was administered to patients with hypercholesterolemia as a single drag at a dose of 0.5 g tablets twice a day for at least 6 months; 71% patients displayed a reduction of LDL-CHL; 90% had a reduction of HDL-CHL (Baldassarre (1997) J. Cardiovasc. Pharmacol. 30:784-789).
  • probucol-treated patients had 15% lower total CHL and 35% lower HDL-CHL compared with controls.
  • LDL from probucol treated individuals was more resistant to oxidation by Cu and showed a 13 times lower formation of lipid peroxides; a 97% reduction in macrophage degradation and close to 90% less decrease in LDL receptor binding following oxidation as compared with controls was also seen (Regnstrom (1996) Atherosclerosis 125:217-229).
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the treatment and prevention of hypercholesterolemia and hyperlipidemia.
  • the probucol esters of the invention are useful as pharmaceuticals in the treatment and prevention of atherosclerotic vascular disease.
  • the invention provides a method for the treatment of an atherosclerotic cardiovascular disease in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the cardiovascular disease.
  • the compositions of the invention can be pharmacologically effective by decreasing the amount of oxidatively damaged LDLs that are believed to play a critical role in the pathogenesis of atherosclerotic vascular disease.
  • Macrophages exposed to increased levels of LDL generate an intracellular oxidative response.
  • Macrophage mediated oxidation of LDL to ox-LDL is cytotoxic to macrophages due to oxidative damage of lysosomal membranes, with ensuing destabilization and leakage to the cytosol of lysosomal contents, such as hydrolytic enzymes, causing degeneration into foam cells and apoptosis.
  • Reactive oxygen species-mediated mitochondrial-dependent pathways also contribute to the apoptotic process by causing nuclear damage.
  • This nuclear damage in the form of DNA strand breakage is mediated as a normal consequence of this increased oxidative stress, which is a signal to increase p53 protein levels and apoptosis (programmed cell death).
  • This macrophage cell death is believed to contribute to the formation of atherosclerotic plaques.
  • Mass spectrometric analysis of protein oxidation products isolated from atherosclerotic tissue also implicate tyrosyl radical, reactive nitrogen intermediates and hypochlorous acid in LDL oxidation and lesion formation in vivo.
  • Hypochlorous acid is generated by the phagocytic enzyme myeloperoxidase, which can also generate tyrosyl radical and reactive nitrogen intermediates.
  • Cellular lipoxygenases also play a role at certain stages.
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the prevention of or decrease in the rate of formation of tyrosyl radicals, reactive nitrogen intermediates, hypochlorous acid, macrophage foam cell formation, and atherosclerotic plaques.
  • the invention provides a method for the treatment of a central or a peripheral neuropathy with an inflammatory component in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the neuropathy.
  • the probucol esters of this invention are particularly useful in inhibiting oxidation and its resultant damage in disorders and trauma of the central and peripheral nervous systems that involve an inflammatory component. This results both from their anti-oxidant properties and because, once introduced into the system, their ability to rapidly equilibrate in various anatomical compartments.
  • probucol is thought to have little or no access to the central nervous system (CNS), it is believed that the probucol esters of the invention may have enhanced access into the central nervous system. Furthermore, probucol has been observed to mitigate the symptoms of severe painful peripheral neuropathy in patients with advanced .AIDS (Nagourney, et al., (1994) abstract, International AIDS meeting).
  • Oxidative stress has been implicated in both normal aging and in various neurodegenerative disorders and may be a common mechanism underlying various forms of neuronal cell death including necrosis, apoptosis, and excitotoxicity.
  • Peripheral nervous system pathologic conditions that can be treated with the probucol esters of the invention include, e.g., neurodegenerative diseases, trauma, and diabetes (increased oxygen free radical activity, coupled with reduced protection against oxidative stress, plays a role in the etiology of neurovascular abnormalities in diabetes mellitus, Cameron (1994) Diabetologia 37:449-459; see also, Van Dam (1997) Neuroscience Research Communications 21 (1): 41-48).
  • Central nervous system pathologic conditions that can be treated or ameliorated with the probucol esters of the invention include, e.g., Friedrich's disease, Parkinson's disease, Alzheimer's disease, Huntington's disease, Pick's disease (a form of frontotemporal dementia), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).
  • the degeneration of neurons in Parkinson's disease (PD) involves oxidative stress as manifested by increased lipid peroxidation and oxidative DNA damage in various areas of brain, including the substantia nigra, caudate nucleus, and putamen (Alam (1997) J. Neurochem. 69:1326-1329).
  • Oxidative damage in PD is caused, in part, by excessive formation of reactive oxygen species and loss of systems involved with scavenging or preventing the formation of such radicals from hydrogen peroxide generated as a consequence of dopamine oxidation (through autoxidation and deamination) (Youdim (1994) Life Sci. 55:2077-2082).
  • Oxidative stress-mediated neuronal loss is in part mediated by a decline in the antioxidant molecule glutathione (GSH).
  • GSH plays multiple roles in the nervous system including free radical scavenger, redox modulator of ionotropic receptor activity, and possibly, as neurotransmitter.
  • GSH depletion can enhance oxidative stress and increase levels of excitotoxic molecules, thus initiating cell death in distinct neuronal populations.
  • Oxidative stress and diminished GSH is associated with the pathogenesis of amyotrophic lateral sclerosis (ALS, or "Lou Gehrig's disease”), Parkinson's disease, and Alzheimer's disease (Bains (1997) Brain Res. Rev. 25:335-358).
  • Free radical and oxidative stress induced injury also mediate glutamate neurotoxicity causative for several neurodegenerative disorders including, cerebrovascular disease and accidents ("stroke”), seizure disorders, epilepsy, Huntington's disease,
  • N-methyl-D-aspartate (NMD A) receptor subtype of glutamate receptors results in the influx of calcium which binds calmodulin and activates neuronal nitric oxide synthase (nNOS), to convent L-arginine to citralline and nitric oxide (NO).
  • nNOS neuronal nitric oxide synthase
  • NO can be neurotoxic; most of the neurotoxic actions of NO are mediated by peroxynitrite
  • Most traumas to the central nervous system such as skull fracture and its resulting edema, brain hemorrhages, shearing lesions, subdural and epidural hematoma, and spinal cord injury (e.g., mechanical injury due to compression or flexion of the spinal cord), have at least one damaging inflammatory component.
  • Probucol has been found to be efficacious in treating and ameliorating neurodegenerative disease.
  • antioxidant agents including probucol
  • oxidative insults iron, hydrogen peroxide, and tert-butyl hydroperoxide
  • beta-amyloid peptides mediate pathogenesis in Alzheimer's disease.
  • oxidative insults iron, hydrogen peroxide, and tert-butyl hydroperoxide
  • beta-amyloid peptides mediate pathogenesis in Alzheimer's disease.
  • Increasing basal levels of oxidative stress by pretreating cultures with subtoxic doses of iron significantly increased neuronal vulnerability to beta-amyloid.
  • the ability of beta-amyloid to induce oxidative stress and the demonstration that oxidative stress potentiates beta-amyloid toxicity support the clinical use of the antioxidant probucol esters of the invention in the treatment and prevention of Alzheimer's disease.
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the prevention and/or treatment of free radical and oxidative stress induced neurologic disease and injury, glutamate neurotoxicity, and disorders and trauma of the central and peripheral nervous system.
  • the compound preferably is administered parenterally, such as by intravenous injection or injection directly into the central nervous system (e.g., intrathecal).
  • the anti-oxidant probucol esters of the invention are effective pharmaceutical agents in the treatment and control of opthalmic disorders, such as cataracts and macular degeneration.
  • the invention provides a method for the treatment of an opthalmic disorder in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the opthalmic disorder. While the invention is not limited to or by a particular theory of operation, the compositions of the invention can be pharmacologically efficacious by inhibiting the oxidation of lipids, with resultant vessel atherosclerosis, in the vasculature of the eye.
  • age-related macular degeneration is a vascular disorder that is a manifestation of the hemodynamic consequence of the process of lipoid infiltration, or atherosclerosis of the vessels of the eye.
  • the resultant decrease in blood perfusion leads to the atrophic form of age-related macular degeneration (Friedman (1997) Am. J. Ophthalmol. 124:677-682 ).
  • anti-oxidants are particularly effective in the prevention and treatment of atherosclerotic lesions. .Antioxidants have also been shown to be anti-cataract agents, protecting the lens from oxidative stress.
  • peroxidase an antioxidant enzyme
  • the probucol esters of the invention can be extremely efficacious, preferred reagents for the treatment of macular degeneration, cataracts, and opthalmic disorders in general.
  • the probucol esters of this invention functioning as anti-oxidants, are useful in the treatment of hearing loss.
  • Oxidative stress and reactive oxygen species have been implicated in hearing loss resulting from noise-induced coclear damage (see, e.g., Prasher (1998) Lancet 352:1240-1242).
  • the present invention provides a method for the treatment of hearing loss.
  • the probucol esters of the invention can be extremely efficacious and preferred reagents for the treatment of hearing loss.
  • the probucol esters of this invention functioning as anti-oxidants, are useful in the treatment of cancer.
  • the invention provides a method for the treatment of a drag- induced oxidative stress in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the drug-induced oxidative stress.
  • Co- administration of anti-oxidants improves the outcome of chemotherapy in subjects with cancer (Kastan (1997) Nature Medicine 11:192-1195).
  • Inflammation typically is followed by the release of potentially damaging substances, such as reactive oxygen intermediates and lipid oxidation products from inflammatory cells.
  • the teratogenicity of many xenobiotics is due at least in part upon their bioactivation by embryonic cytochromes P450, prostaglandin H synthase and lipoxygenases to electrophilic and/or free radical reactive intermediates that covalently bind to or oxidize cellular macromolecules such as DNA, protein and lipid, resulting in in utero death or teratogenesis (Wells (1997) MutatRes. 396:65-78).
  • the invention also provides a method for the treatment of a cancer in a subject comprising administering to the subject a probucol ester in an amount effective to treat the cancer.
  • Probucol has been shown to have a protective, anti-tumor effect.
  • probucol esters can be extremely efficacious, preferred reagents for the prevention and/or treatment of cancer.
  • Probucol esters can be useful in the treatment of any cancer.
  • chemotherapeutic agents also frequently causes non- therapeutic inflammation as a side effect, thus limiting the duration and/or dosage of agent that can be given to the patient.
  • adriamycin cardiomyopathy a side effect of adriamycin administration
  • the major cause of this condition is increased oxidative stress, although the drag's antitumor action in patients may involve other mechanisms (Singal (1997) FASEB J. 11 :931-936).
  • co- administration of probucol esters adjunctively with chemotherapeutic agents is beneficial in the treatment of cancer.
  • the probucol esters of the invention can be administered to subjects before, during and/or after chemotherapy.
  • Preferred routes of administration include intravenous, parenteral and oral routes.
  • the invention provides a method for the treatment of a pulmonary disorder in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the pulmonary disorder. Because they can be easily administered to the respiratory system via inhalation, the probucol esters of this invention are especially useful in the treatment of respiratory disorders having an inflammatory component or that result from exposure to (inhalation of) oxidizing agents or agents which cause tissue inflammation, such as ozone and high concentrations of oxygen itself.
  • the probucol esters of the invention can inhibit oxidation and its subsequent damage that result in or accompany such respiratory disorders and exposures, such as, e.g., acid aspiration, adult/infant respiratory distress syndrome, airway obstructive disease, asthma, bronchiolitis, bronchopulmonary dysplasia, cancer, chronic obstructive pulmonary disease ("COPD"), cystic fibrosis, emphysema, HIV-associated lung disease, idiopathic pulmonary fibrosis, immune-complex-mediated lung injury, ischemia-reperfusion injury, mineral dust pneumoconiosis, drag-induced lung disease, silo-filler's disease, and byssinosis (an occupational lung disease in textile mill workers exposed to the respirable dusts of cotton, hemp, and flax; see Bates (1995) Exp.
  • COPD chronic obstructive pulmonary disease
  • cystic fibrosis emphysema
  • HIV-associated lung disease id
  • the compound is preferably delivered by inhalation; however, it can be given orally and parenterally as well.
  • the compound can be delivered as an aerosol, mist or powder.
  • the invention provides a method for the treatment of an arthritis having an inflammatory component in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the arthritis.
  • Rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and the like are pathologic conditions which have an inflammatory component.
  • MDA malondialdehyde
  • IL-1 alpha interleukin 1 alpha
  • IL-1 beta interleukin 1 beta
  • TNF-alpha tumor necrosis factor alpha
  • probucol esters as antioxidants, are useful in treating, ameliorating or preventing arthritis.
  • the compounds are preferably delivered orally, intravenously, parenterally, or transdermally for this purpose.
  • the invention provides a method for the treatment of pre-eclampsia and eclampsia in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the pre-eclampsia or eclampsia.
  • Increased free-radical activity is involved in the pathogenesis of pre-eclampsia. Radical-scavenging antioxidants are consumed by an increased free-radical activity in pre-eclampsia.
  • the compounds are preferably delivered orally, intravenously, or parenterally.
  • the invention provides a method for the treatment of infertility due to increased oxidative stress in a subject comprising administering to the subject a probucol ester of the invention in an amount effective to treat the infertility.
  • Excessive generation of reactive oxygen species by abnormal spermatozoa and by contaminating leukocytes has been identified as one of the few defined etiologies for male infertility.
  • glutathione an antioxidant administered in vivo to patients who had infertility (whose etiology may have been in part due to excessive oxidative stress in the epididymis during spermatogenesis) improved the function of ejaculated spermatozoa (Irvine (1996) Rev.
  • the probucol esters of the invention can be useful in the treatment of some types of male infertility.
  • oxidative stress may be related to some types of female infertility; therefore, the probucol esters of this invention can be useful in these cases.
  • the invention provides a method for the treatment of erectile dysfunction. This condition is known to be mediated at least in part by abnormal reactive oxygen species metabolism. .Antioxidant compounds play important roles in ameliorating reactions leading to erectile dysfunction. The compounds of the present invention are therefore useful in the treatment of erectile dysfunction.
  • the invention provides a method for the treatment of alopecia (hair loss).
  • the invention provides a method for the treatment of endometriosis. This condition is known to be mediated at least in part by oxidative stress and reactive oxygen species. Antioxidant compounds play important roles in ameliorating reactions leading to endometriosis. Thus, the probucol esters of the present invention, as anti-oxidants, are useful in the treatment of endometriosis.
  • the probucol esters of the invention can be formulated as pharmaceuticals for administration in a variety of ways.
  • Typical routes of administration include both enteral and parenteral. These include, e.g, without limitation, subcutaneous, intramuscular, intravenous, intraperitoneal, intramedullary, intrapericardiac, intrabursal, intradermal, oral, sublingual, ocular, nasal, topical, transdermal, transmucosal, intrathecal, or rectal.
  • the mode of administration can be, e.g., via swallowing, inhalation, injection or topical application to a surface (e.g., eyes, mucous membrane, skin). Particular formulations typically are appropriate for specific modes of administration.
  • Various contemplated formulations include, e.g., aqueous solution, solid, aerosol, liposomal and transdermal formulations.
  • aqueous solutions that can be used in formulations for enteral, parenteral or transmucosal drug delivery include, e.g., water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like.
  • the formulations can contain pharmaceutically acceptable auxilliary substances to enhance stability, deliverability or solubility, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.
  • Additives can also include additional active ingredients such as bactericidal agents, or stabilizers.
  • the solution can contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate.
  • These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered.
  • the resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • Aqueous solutions are appropriate for injection and, in particular, for intravenous injection.
  • the intravenous solution can include detergents and emulsifiers such as lipids.
  • Aqueous solutions also are useful for enteral administration as tonics and administration to mucous or other membranes as, e.g., nose or eye drops.
  • the pharmaceutical composition of the invention contains a probucol ester in an amount of about 1 mg/ml to about 100 mg/ml, more preferably about 10 mg/ml to about 50 mg/ml.
  • Solid formulations can be used for enteral administration. They can be formulated as, e.g., pills, tablets, powders or capsules.
  • conventional nontoxic solid carriers can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
  • a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10%-95% of active ingredient.
  • a non-solid formulation can also be used for enteral (oral) administration.
  • the carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. See Sanchez, et al., U.S. Patent No. 5,494,936.
  • Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • a unit dosage form such as a tablet, can be between about about 50 mg/unit to about 2 grams/unit, preferably between about 100 mg/unit to about 1 gram/unit.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated can be used in the formulation.
  • penetrants are generally .known in the art, and include, e.g., for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents can be used to facilitate permeation.
  • Transmucosal administration can be through nasal sprays, for example, or using suppositories.
  • the agents are formulated into ointments, creams, salves, powders and gels.
  • the transdermal delivery agent can be DMSO.
  • Transdermal delivery systems can also include, e.g., patches.
  • Topical administration is particularly useful in the treatment of wounds.
  • a pharmaceutical composition comprising, e.g., hyaluronic acid, can be administered in the appropriate phaimaceutically acceptable formulation and administered topically. See, e.g., Polarek et al., Wounds: a Compendium of Clinical Research and Practice, 6:46-53 (1994).
  • the probucol esters can also be administered in sustained delivery or sustained release mechanisms, which can deliver the formulation internally.
  • sustained delivery or sustained release mechanisms can deliver the formulation internally.
  • biodegradeable microspheres or capsules or other biodegradeable polymer configurations capable of sustained delivery of a composition e.g., a probucol ester pharmaceutical
  • a composition e.g., a probucol ester pharmaceutical
  • the probucol ester formulation can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. See, e.g., Patton (1998) Biotechniques 16:141- 143; inhallation delivery systems by, e.g., Dura Pharmaceuticals (San Diego, CA) , Aradigm (Hayward, CA), Aerogen (Santa Clara, CA), Inhale Therapeutic Systems (San Carlos, CA), and the like.
  • the pharmaceutical formulation can be administered in the form of an aerosol or mist.
  • the formulation can be supplied in finely divided form along with a surfactant and propellant.
  • the surfactant preferably is soluble in the propellant.
  • Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol, and the polyoxyethylene and polyoxypropylene derivatives of these esters.
  • the surfactant can constitute 0J%-20% by weight of the composition, preferably 0.25%-5%.
  • the balance of the fo ⁇ nulation is ordinarily propellant.
  • Liquefied propellants are typically gases at ambient conditions, and are condensed under pressure.
  • suitable liquefied propellants are the lower alkanes containing up to 5 carbons, such as butane and propane; and preferably fluorinated or fluorochlorinated alkanes. Mixtures of the above can also be employed.
  • a container equipped with a suitable valve is filled with the appropriate propellant, containing the finely divided compounds and surfactant.
  • a nebulizer or aerosolizer device for administering probucol esters of this invention typically delivers an inhaled dose of about 1 mg/m to about 50 mg/m .
  • the methods of the invention inhibit oxidation and oxidative damage in a subject and treat or prevent a variety of injuries, diseases and conditions, including, e.g., viral infections, reperfusion injury, restenosis, hypercholesterolemia, peripheral and central neuropathy, opthalmic disorders, pulmonary disorders, cardiovascular disease, diabetic neurovascular pathology, eclampsia, and conditions caused or exacerbated by oxidative stress.
  • the amount of probucol ester adequate to accomplish this is defined as a
  • dosage schedule and amounts effective for this use i.e., the "dosing regimen” will depend upon a variety of factors, including frequency of dosing, the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.
  • the dosage regimen must also take into consideration the pharmacokinetics, i.e., the probucol ester's rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Komura (1997) "Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol," Eur. J. Drug Metab. Pharmacokinet. 22:201-206; Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996)
  • Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician.
  • the pharmaceutical formulations should provide a quantity of a probucol ester sufficient to treat the patient effectively.
  • the total effective amount of a probucol ester of the present invention can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of time, or can be administered using a fractionated treatment protocol, in which the multiple doses are administered over a more prolonged period of time.
  • a probucol ester of the present invention concentration of a probucol ester of the present invention required to obtain an effective dose (i.e., a "therapeutically effective dose") in a subject depends on many factors including, e.g., the pharmacokinetics of the prodrag and of its hydrolysis product, the age and general health of the subject, the route of administration, the number of treatments to be administered and the judgment of the prescribing physician. In view of these factors, the skilled artisan would adjust the dose so as to provide an effective dose for a particular use.
  • the invention provides a composition comprising a bio-organic material and an amount of a probucol ester of the invention effective to inhibit oxidation of the bio- organic material.
  • the bio-organic material can be blood plasma, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, virases, foods, drinks, implant materials or implantable devices (e.g., plastics, artificial heart valves or joints, collagens), medical materials (e.g., tubing for catheterization, intubation, IVs) and containers (e.g., blood bags, storage containers), and the like.
  • the composition can contain a mixture of different probucol esters of the invention (e.g., probucol monophosphate, probucol diphosphate, or diphospho-probucol) in varying amounts.
  • Example 1 Synthesis of Probucol Phosphate Esters The following example details the synthesis of the probucol monophosphate and probucol diphosphate esters of the invention.
  • the organic phase was washed first with 1M phosphate buffer, pH 4.5, and then with brine-HCl. After drying over sodium sulfate and removing (evaporating) volatile solvents, probucol monophosphate (free acid) was obtained as a solid residue, weighing 0J5 gm, 16.2% yield.
  • the product was characterized by electrospray mass spectroscopy and nuclear magnetic resonance spectroscopy.
  • Electrospray analysis electrospray MS m/z 677 [M+H] + , 699 [M+Na] + .
  • the following example details the use of the probucol monophosphate and probucol diphosphate esters of the invention as antioxidants; and, using an in vitro cell culture model, demonstrates that they are effective as antioxidants in a biological system.
  • Example 3 Probucol Esters Protecting Against LDL Oxidation by Copper and Horseradish Peroxidase/ Hydrogen Peroxide.
  • the following example describes the use of the probucol monophosphate and probucol diphosphate esters of the invention as antioxidants in the protection of LDL aginast oxidation by copper and by horseradish peroxidase and hydrogen peroxide.
  • LDL in the presence of horse radish peroxidase/hydrogen peroxide exhibited a characteristic time course of oxidation, with a lag phase of about two hours followed by an onset of oxidation that became maximal after about five hours.
  • the addition of 5 uM probucol or 5 uM probucol monophosphate delayed the lag phase and completely eliminated the onset of oxidation to about seven hours.
  • probucol and probucol monophosphate are potent antioxidants. They also demonstrate that probucol diphosphate is an effective antioxidant, even in the absence of enzymes needed to convert the diphosphate probucol to its hydrolysis products probucol monophosphate and probucol.
  • the following example details the use of the probucol diphosphate ester of the invention to prevent oxidation by the enzyme myeloperoxidase.
  • the protective effect of probucol diphosphate on myeloperoxidase (MPO) oxidation of 1.4 mM tetramethylbenzidine was assayed by measuring the oxidation product at 665 nm.
  • the reagents used were myeloperoxidase from human leukocytes (cat. #M6908,
  • MPO 0.025 standard unit
  • TMBD TMBD were incubated at room temperature in acetate buffer (50 mM, pH 5.4) containing 8% of N,N- dimethyl foraia ide (DMF) and various concentration of probucol diphosphate (5 uM, 10 uM, 20 uM, 30 uM and 40 uM).
  • DMF N,N- dimethyl foraia ide
  • probucol diphosphate 5 uM, 10 uM, 20 uM, 30 uM and 40 uM.
  • the reaction was started by adding 300 uM H 2 O , stopped by adding 10 ug/mL of catalase.
  • the reaction mixture was diluted with 0.2M acetic acid in the ratio 1 : 1 and then the UV spectra were measured.
  • Example 5 Stability of Probucol Esters In Aqueous Solutions.
  • the following example details the stability of the probucol esters of the invention in an aqueous solution.
  • Probucol diphosphate was dissolved in a 1 : 1 mixture of 0J M sodium phosphate buffer and ethanol.
  • Ethanol is ued as a cosolvent in order to help in the dissolution of probucol monophosphate and probucol, and to maintain solution clarity.
  • Example 6 Enzymatic Hydrolysis of Probucol Esters The following example describes the enzymatic conversion of probucol diphosphate to probucol monophosphate in an aqueous solution. Alkaline phosphatase.
  • Probucol diphosphate disodium salt (2 mg) and 5 units of alkaline phosphatase were dissolved in 5 ml of glycine buffer, pH 10.4, containing 1 mM MgSO 4 and 0.2 mM ZnSO 4 . After 20 hours at 37°C, analysis by standard thin layer chromatography showed the presence of 6% probucol monophosphate. These results demonstrate that probucol diphosphate is enzymatically hydrolyzed by alkaline phosphatase.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne le domaine des produits pharmaceutiques, et plus spécifiquement de nouveaux esters de probucol solubles dans l'eau destinés à être administrés comme antioxydants, et des promédicaments de probucol. La présente invention concerne encore des formulations pharmaceutiques comprenant de nouveaux esters phosphoriques de probucol solubles dans l'eau.
PCT/US1998/023746 1997-11-10 1998-11-09 Esters de probucol et leurs utilisations WO1999024400A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13873/99A AU1387399A (en) 1997-11-10 1998-11-09 Probucol esters and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6526797P 1997-11-10 1997-11-10
US60/065,267 1997-11-10

Publications (1)

Publication Number Publication Date
WO1999024400A1 true WO1999024400A1 (fr) 1999-05-20

Family

ID=22061517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023746 WO1999024400A1 (fr) 1997-11-10 1998-11-09 Esters de probucol et leurs utilisations

Country Status (2)

Country Link
AU (1) AU1387399A (fr)
WO (1) WO1999024400A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077014A1 (fr) * 1999-06-11 2000-12-21 Kyowa Hakko Kogyo Co., Ltd. Phosphates d'aryle
WO2002000224A1 (fr) * 2000-06-29 2002-01-03 Hunter-Fleming Limited 7-beta-hydroxysteroides neuroprotecteurs
US6602914B2 (en) 1997-05-14 2003-08-05 Atherogenics, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
US6881860B2 (en) 2000-04-11 2005-04-19 Atherogenics, Inc. Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
WO2005039596A1 (fr) * 2003-10-17 2005-05-06 Amylin Pharmaceuticals, Inc. Silylphenols pouvant ameliorer la sante vasculaire
EP1594824A2 (fr) * 2003-01-13 2005-11-16 Atherogenics, Inc. Procede de preparation d'esters et d'ethers de probucol et ses derives
US7166605B2 (en) 2002-03-22 2007-01-23 Nicox, S.A. Probucol nitro-derivatives
WO2007032557A1 (fr) * 2005-09-15 2007-03-22 Otsuka Pharmaceutical Co., Ltd. Médicament combiné contenant du probucol et un dérivé de tétrazolylalcoxy-dihydrocarbostyrile présentant des effets suppresseurs du superoxyde
US7294737B2 (en) 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
WO2008053374A2 (fr) * 2006-07-20 2008-05-08 Birgit Neudecker Agent à effet protecteur et régénérateur contenant du probucol appliqué de façon topique
WO2008111662A1 (fr) 2007-03-09 2008-09-18 Otsuka Pharmaceutical Co., Ltd. Médicament traitant la bronchopneumopathie chronique obtructive
US7718639B2 (en) 2000-06-29 2010-05-18 Hunter-Fleming Limited 7-hydroxyepiandrosterone having neuroprotective activity
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes
WO2019241156A1 (fr) * 2018-06-11 2019-12-19 Loma Linda University Procédés de retardement et d'inversion de la progression de la maladie d'alzheimer
WO2021248210A1 (fr) * 2020-06-11 2021-12-16 Curtin University Méthodes de traitement et formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, 1 January 1900, Columbus, Ohio, US; abstract no. 73:45047, NEUWORTH M B, ET AL: "Synthesis and Hypocholesterolemic Activity of Alkylidene Dithio Bisphenols" XP002917134 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087645B2 (en) 1997-05-14 2006-08-08 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US7375252B2 (en) 1997-05-14 2008-05-20 Atherogenics, Inc. Compounds and method for the inhibition of the expression of VCAM-1
US6602914B2 (en) 1997-05-14 2003-08-05 Atherogenics, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US6617352B2 (en) 1997-05-14 2003-09-09 Atherogenics, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6828447B2 (en) 1997-05-14 2004-12-07 Atherogenics, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US7189870B2 (en) 1997-05-14 2007-03-13 Atherogenic, Inc. Compounds and methods for the inhibition of the expression of VCAM-1
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
WO2000077014A1 (fr) * 1999-06-11 2000-12-21 Kyowa Hakko Kogyo Co., Ltd. Phosphates d'aryle
US7183317B2 (en) 2000-04-11 2007-02-27 Atherogenics, Inc. Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
US6881860B2 (en) 2000-04-11 2005-04-19 Atherogenics, Inc. Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
CN100441189C (zh) * 2000-06-29 2008-12-10 亨特-弗莱明有限公司 具有神经保护作用的7-β-羟基类固醇
CZ305306B6 (cs) * 2000-06-29 2015-07-22 Hunter-Fleming Limited Použití 7β-hydroxysteroidu nebo jeho farmaceuticky přijatelného esteru nebo jeho jiného derivátu pro přípravu léčiva pro ochranu před poškozením nervových buněk
US7718639B2 (en) 2000-06-29 2010-05-18 Hunter-Fleming Limited 7-hydroxyepiandrosterone having neuroprotective activity
WO2002000224A1 (fr) * 2000-06-29 2002-01-03 Hunter-Fleming Limited 7-beta-hydroxysteroides neuroprotecteurs
US7166605B2 (en) 2002-03-22 2007-01-23 Nicox, S.A. Probucol nitro-derivatives
EP1594824A2 (fr) * 2003-01-13 2005-11-16 Atherogenics, Inc. Procede de preparation d'esters et d'ethers de probucol et ses derives
EP1594824A4 (fr) * 2003-01-13 2007-04-04 Atherogenics Inc Procede de preparation d'esters et d'ethers de probucol et ses derives
WO2005039596A1 (fr) * 2003-10-17 2005-05-06 Amylin Pharmaceuticals, Inc. Silylphenols pouvant ameliorer la sante vasculaire
US7294737B2 (en) 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
KR101299320B1 (ko) * 2005-09-15 2013-09-03 오츠카 세이야쿠 가부시키가이샤 초과산화물 억제제 효과를 갖는 프로부콜 및테트라졸릴알콕시-디히드로카르보스티릴 유도체를 함유하는조합 약물
WO2007032557A1 (fr) * 2005-09-15 2007-03-22 Otsuka Pharmaceutical Co., Ltd. Médicament combiné contenant du probucol et un dérivé de tétrazolylalcoxy-dihydrocarbostyrile présentant des effets suppresseurs du superoxyde
EP2275106A1 (fr) * 2005-09-15 2011-01-19 Otsuka Pharmaceutical Co., Ltd. Médicament combiné contenant du probucol et un dérivé de tétrazolylalcoxy-dihydrocarbostyrile présentant des effets suppresseurs du superoxyde
AU2006289752B2 (en) * 2005-09-15 2011-06-09 Otsuka Pharmaceutical Co., Ltd. Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
US8580818B2 (en) 2005-09-15 2013-11-12 Otsuka Pharmaceutical Co., Ltd. Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
WO2008053374A3 (fr) * 2006-07-20 2009-03-26 Birgit Neudecker Agent à effet protecteur et régénérateur contenant du probucol appliqué de façon topique
WO2008053374A2 (fr) * 2006-07-20 2008-05-08 Birgit Neudecker Agent à effet protecteur et régénérateur contenant du probucol appliqué de façon topique
KR101442874B1 (ko) * 2007-03-09 2014-09-19 오츠카 세이야쿠 가부시키가이샤 만성 폐색성 폐질환 치료제
WO2008111662A1 (fr) 2007-03-09 2008-09-18 Otsuka Pharmaceutical Co., Ltd. Médicament traitant la bronchopneumopathie chronique obtructive
JP2010520872A (ja) * 2007-03-09 2010-06-17 大塚製薬株式会社 慢性閉塞性肺疾患治療剤
US8252840B2 (en) 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes
WO2019241156A1 (fr) * 2018-06-11 2019-12-19 Loma Linda University Procédés de retardement et d'inversion de la progression de la maladie d'alzheimer
EP3801221A4 (fr) * 2018-06-11 2022-03-30 Loma Linda University Procédés de retardement et d'inversion de la progression de la maladie d'alzheimer
WO2021248210A1 (fr) * 2020-06-11 2021-12-16 Curtin University Méthodes de traitement et formulations

Also Published As

Publication number Publication date
AU1387399A (en) 1999-05-31

Similar Documents

Publication Publication Date Title
WO1999024400A1 (fr) Esters de probucol et leurs utilisations
EP0637959B1 (fr) Analogues solubles de probucol
US20050222046A1 (en) Pharmaceutical preparations of glutathione and methods of administration thereof
JP2001507696A (ja) グルタチオンの医薬製剤およびその投与方法
JP2004517810A (ja) 片頭痛の処置のためのプロポフォールの水溶性プロドラッグ
KR100272483B1 (ko) 지질 대사 개선제
US20040265369A1 (en) Compounds that inhibit caspase activity for treating glaucoma
AU2007203159A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
WO1997010236A1 (fr) Esters d'acides carboxyliques non steroidiens anti-inflammatoires
EP0546796A1 (fr) Utilisation de L-arginine et ses analogues pour le traitement de l'athérosclerose
US5686450A (en) Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
WO2017091737A1 (fr) Formulations pharmaceutiques
EP2732817B1 (fr) Composé destiné à être utilisé dans le traitement d'une lésion associée à l'exposition à du phosgène ou du chlore gazeux
CN111479574A (zh) 用于治疗和预防细胞外组蛋白介导的病理的化合物
EP0661053A1 (fr) Utilisation des toropherol acide ascorbique phosphates pour des maladies hemorrhoidales
EP1140115B1 (fr) Complexes phospholipidiques de proanthocyanidine a2 comme agents anti-atherosclereux
EP2139465B1 (fr) Composition comprenant de la s-allylmercapto-n-acetylcysteine pour une régulation positive du taux de glutathione cellulaire
WO1992003130A1 (fr) Utilisation de composes d'aryle hydroxyuree pour le traitement de l'atherosclerose
US6075053A (en) Method of reducing or reversing neuropathy
AU709131B2 (en) Antioxidant compounds
US6077838A (en) Method of treating hangover
US5854287A (en) D-Propranolol metabolites useful for antioxidant activities
US6034126A (en) Method for treating glycol poisoning
US6225295B1 (en) Method of treating acetaminophen overdose
EP1704857B1 (fr) Probucol spiroquinone ou probucol diphenoquinone pour son utilisation dans le traitement de faibles taux de cholesterol hdl

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA